LivaNova (NASDAQ:LIVN) Trading 13.8% Higher After Strong Earnings

LivaNova PLC (NASDAQ:LIVN) shares traded up 13.8% during trading on Wednesday following a stronger than expected earnings report. The stock traded as high as $65.97 and last traded at $65.5490. 225,348 shares changed hands during trading, a decline of 71% from the average session volume of 777,609 shares. The stock had previously closed at $57.59.

The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The firm had revenue of $362.30 million for the quarter, compared to analysts’ expectations of $346.05 million. During the same quarter in the prior year, the firm posted $0.88 earnings per share. LivaNova’s revenue for the quarter was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS.

Wall Street Analyst Weigh In

Several research firms have recently commented on LIVN. Piper Sandler reaffirmed an “overweight” rating and set a $85.00 target price on shares of LivaNova in a report on Thursday, February 19th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $66.00 target price on shares of LivaNova in a report on Friday, January 9th. Stifel Nicolaus set a $80.00 target price on LivaNova in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a report on Friday, March 27th. Finally, Barclays upped their target price on LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Seven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and an average target price of $74.78.

Hedge Funds Weigh In On LivaNova

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. State of Michigan Retirement System grew its holdings in LivaNova by 1.5% in the 1st quarter. State of Michigan Retirement System now owns 13,111 shares of the company’s stock worth $833,000 after buying an additional 200 shares in the last quarter. Principal Financial Group Inc. grew its holdings in LivaNova by 1.9% in the 1st quarter. Principal Financial Group Inc. now owns 179,529 shares of the company’s stock worth $11,411,000 after buying an additional 3,306 shares in the last quarter. Oregon Public Employees Retirement Fund grew its holdings in LivaNova by 2.7% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 11,250 shares of the company’s stock worth $715,000 after buying an additional 300 shares in the last quarter. Y Intercept Hong Kong Ltd grew its holdings in LivaNova by 56.8% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 18,169 shares of the company’s stock worth $1,155,000 after buying an additional 6,585 shares in the last quarter. Finally, Inspire Investing LLC bought a new position in LivaNova in the 1st quarter worth approximately $1,627,000. 97.64% of the stock is owned by institutional investors.

LivaNova Price Performance

The firm has a market capitalization of $3.62 billion, a P/E ratio of -14.94 and a beta of 0.82. The business has a fifty day moving average of $64.01 and a 200-day moving average of $61.94. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.16 and a current ratio of 1.36.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.